Scott B. Ullem - 17 May 2021 Form 4 Insider Report for Edwards Lifesciences Corp (EW)

Role
CVP, Chief Financial Officer
Signature
Linda J. Park, Attorney-in-Fact
Issuer symbol
EW
Transactions as of
17 May 2021
Transactions value $
-$909,934
Form type
4
Filing time
19 May 2021, 16:30:58 UTC
Previous filing
12 May 2021
Next filing
29 Nov 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction EW Common Stock Options Exercise $0 +17,193 +57% $0 47,299 17 May 2021 Direct F1
transaction EW Common Stock Tax liability -$147,032 -1,643 -3.5% $89.49 45,656 17 May 2021 Direct
transaction EW Common Stock Tax liability -$762,902 -8,525 -19% $89.49 37,131 17 May 2021 Direct
holding EW Common Stock 229,251 17 May 2021 By Trust

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction EW Performance Rights Options Exercise $0 -17,193 -100% $0* 0 17 May 2021 Common Stock 17,193 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On May 17, 2018, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 3, 2021, the Compensation Committee of the Board of Directors determined that 175% of the target number of shares would vest as of May 17, 2021, and the actual number of shares vested are reflected on this Form 4.

Remarks:

This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person.